"Stocks are so low that the best are bound to attract bargain-hunters ... eventually," says Timothy Lutts. One such value he highlights in The Cabot Stock of the Month Report is Royal Gold (NASDAQ: RGLD).

He explains, "Royal Gold doesn't own any gold mines. It doesn't mine gold. It doesn't buy gold. And it doesn't sell gold. It simply owns the rights to royalties from a variety of precious metals producers."

"The major benefit of Royal Gold's approach to the gold business is that it involves no capital costs, no operating costs and no legal or environmental liabilities. The major drawback? Well, we haven't found it yet.

"Royal Gold is not large. It has annual revenues of just $69 million and 34 million shares outstanding. However, Royal Gold is the biggest company in the world that derives its revenues solely from precious metal royalties.

In The Cabot Benjamin Graham Value Letter -- which assesses stocks based on Graham's value investing critera, editor J. Royden Ward takes a look at Wal-Mart Stores (NYSE: WMT).

"In this month's Classic Benjamin Graham Value Model, our calculation suggests that the Dow is overvalued at 12,370 and undervalued at 8,305; as such, today the market is extremely undervalued.

"This low-risk environment means it's probably a great time to add risk by dabbling in our recommended stocks such as Wal-Mart Stores.

"How cheap is it? The recent decline in WMT shares has created an outstanding buying opportunity for investors. WMT shares now sell at only 12.3 times forward EPS with a dividend yield of 2.0%.

"Our favorite current investment idea is Netflix (NASDAQ: NFLX)," says Michael Cintolo, editor of The Cabot Top Ten Report, which each week reviews ten issues that have been showing strong price momentum.

"Netflix bolted higher on a great earnings report last week, and impressively, followed through to the upside for a few days. Bad economic times seem to mean good news for Netflix, as an evening at home with a few DVDs is way easier on the budget than even a bargain matinee at the Cineplex.

"That's the message of Netflix' boffo quarterly results that came out on January 26. Earnings walloped analysts' estimates and more than twice the predicted number of new subscribers signed up.

"Stryker (NYSE: SYK) is a bargain at 15.1x next 12-month EPS," says J. Royden Ward, editor of The Cabot Benjamin Graham Value Letter, a service which focuses on stocks that would be well-suited to the investing strategy of Ben Graham, legendary value investor and mentor to Warren Buffett.

"Stryker develops, manufactures and sells specialty surgical and medical products. Its orthopedic division makes hip, knee and other implants.

"SYK also makes a wide variety of medical products and instruments ranging from hospital beds to medical video cameras, surgical drills and saws, and instruments for implants.

Health care has long been considered a recession-resistant business. Given the current economic challenges, it's little surprise that in our survey of favorite stocks for the coming year, a number of leading advisors turned to this classic defensive sector.

In this year's Top Stock Picks from 75 advisors report, we found an intriguing group of medical-related stocks, from speculation in emerging biotech to well-established pharmaceutical firms, and from medical products makers to medical services firms focused on increasing health care efficiency and early disease detection.

Mike Cintolo, editor of The Cabot Market Letter, thinks Myriad Genetics (NASDAQ: MYGN) could be a "big winner in 2009," The company is a lead in the new field of cancer predisposition testing. For Mike's full report, read Top Stock Picks '09: Myriad Genetics.

Chuck Carlson, editor of The DRIP Investor, sees both quality and potential in Bristol-Myers Squibb (NYSE: BMY). For Chuck's full report, read Top Stock Picks '09: Bristol-Myers Squibb.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"My top idea for 2009 is Myriad Genetics (NASDAQ: MYGN)," says Mike Cintolo. In The Cabot Market Letter, he looks at "the leader in the new field of cancer predisposition testing."

"Myriad Genetics five tests on the market (covering colon, breast, ovarian, and skin cancer) that tell a patient if his genes make it more likely that he'll get various types of cancer.

"During the past few quarters, revenues from these tests have risen at a 50% annual clip, and there's no sign of that slowing down.

"The company also has a pharmaceutical division, but it's going to spin that off sometime in 2009. That should be a big positive, as the drug development division carries good potential, but also big-time costs. Once the cancer predisposition testing division is on its own, much of that revenue growth is going to fall to the bottom line.